ALSO READChina's Fosun Pharma to buy smaller stake in Gland Pharma for $1.09 bn China's Fosun to buy 74% stake in Gland Pharma for $1.1 bn in revised deal Fosun Pharma to buy 74% stake in Gland for $1.09 billion Govt plans to block $1.3-bn Gland Pharma-Fosun deal Govt set to block $1.3-bn Chinese pharma firm Fosun's takeover of Gland
Since all the conditions precedent of the acquisition of the controlling interest in Gland Pharma have been satisfied boards of directors of Fosun Pharma and Fosun International are pleased to announce that the completion of the acquisition of the controlling interest in Gland Pharma, the companies said in a joint statement.
In the regulatory filing, Fosun Pharma and Fosun International said following the completion of the acquisition, Gland Pharma has become an indirect non-wholly owned subsidiary of Fosun Pharma and Fosun International.
Fosun Pharma and Fosun International indirectly hold approximately 74 per cent equity interest in Gland Pharma, the joint statement added.
However, the Cabinet Committee on Economic Affairs (CCEA) had raised objections to the proposal earlier this year, a development that came amid heightened tensions between India and China over border dispute.
It had said that the "approvals of the relevant PRC authorities in respect of the acquisition have been obtained, and the United States anti-trust filings and Indian anti-trust filings have been completed."
"...no review and approval of the India Foreign Investment Promotion Board and the Cabinet Committee on Economic Affairs of India is required in relation to the transactions contemplated under the amendments to the transaction documents under the relevant Indian foreign investment policies," Fosun Pharma said at that time.
With an increase in the shareholding from the earlier contemplated sale, promoters Ravi Penmetsa and his father P V N Raju will continue on the board of the company Gland Pharma had earlier said in a statement.
Besides, the present management team will be in-charge of the day to day running of the company, it had added.